Alphabet’s Isomorphic Labs eyes $50B valuation in new funding round

Isomorphic Labs, the Alphabet spinoff applying artificial intelligence to drug discovery, is reportedly in talks to raise a new funding round at a valuation of up to $50 billion. Bloomberg cited unnamed sources in its report today, without disclosing the size of the round.

The company’s focus on using AI to accelerate scientific breakthroughs and develop new medicines mirrors broader trends in the sector. Other AI startups in the life-sciences space have also attracted significant investor interest recently, with some pursuing similarly high valuations.

If confirmed, the reported valuation would position Isomorphic Labs as one of the most prominent players in the intersection of AI and biotech. The discussions come amid growing speculation about the potential—and challenges—of AI-driven drug discovery, though the field remains largely unproven at scale.

No investors have been named in the current discussions. Should the round proceed, it could further intensify competition among startups leveraging AI for pharmaceutical development.

Sources: siliconangle.com